Annual General Meeting of MorphoSys AG Approves All Management Proposals
(Thomson Reuters ONE) -
MorphoSys AG /
Annual General Meeting of MorphoSys AG Approves All Management Proposals
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that at
the Company's Annual Shareholder Meeting on Tuesday, 4 June 2013, its
shareholders approved the following management proposals put to vote at the
meeting:
* Granting full discharge of the members of the Management and Supervisory
Boards in respect of their activities during the business year 2012.
* The appointment of PricewaterhouseCoopers AG as auditors of the Company and
the MorphoSys Group for the business year 2013.
* The use of the net earnings of MorphoSys AG, Management and Supervisory
Boards recommended that the net profit of the business year 2012 is carried
forward as accumulated income
* Amendment of the authorization to issue convertible bonds based on the
resolution of the Annual General Meeting on May 14, 2008 and the
corresponding provision of the Articles of Association to avoid shares with
a deviating entitlement to dividend
* The creation of a new Authorized Capital 2013-I with the possibility to
exclude pre-emptive rights of the shareholders
"In 2012 we have seen a fundamental re-rating of the company, which was clearly
linked to the potential value of our pipeline, not our immediate financial
performance. This validates our strategy of investing in proprietary drug
programs to create substantial value for our shareholders" commented Dr. Simon
Moroney, Chief Executive Officer of MorphoSys AG.
At the Annual General Meeting 2013 of MorphoSys AG, 41.6 % of the voting shares
were represented.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1707021/565199.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1707021]
Unternehmensinformation / Kurzprofil:
Datum: 04.06.2013 - 16:00 Uhr
Sprache: Deutsch
News-ID 266477
Anzahl Zeichen: 4940
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 157 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Annual General Meeting of MorphoSys AG Approves All Management Proposals"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
